Available Technology
Bilins as anticancer agents
Technology:
Anticancer agents
Markets Addressed
Therapeutic small molecules
Innovations and Advantages
A remarkable discovery at Harvard Medical School has led to the recognition that a naturally-occurring small molecule and analogs thereof possess potent anticancer properties through their ability to control cell differentiation. According to the invention, bilins are administered to induce terminal differentiation of dividing mammalian cells and thereby halt uncontrolled cell proliferation. This invention represents a major conceptual departure from traditional, signaling pathway-targeted strategies for tissue engineering and for the treatment of both benign and malignant cell proliferative disorders.
Additional Information
Intellectual Property Status: See published U.S. patent applications 20020099085 and 20020169201, each entitled, "Compounds and methods for regulating cell differentiation". Allowed U.S. patent claims cover administration of bilins to induce differentiation of lymphoblasts, as well as colon adenocarcinoma, thyroid carcinoma and liposarcoma cells. The invention is available for exclusive license.
Tweet
Inventor(s):
Falchuk, Kenneth H.
Categories:
For further information, please contact:
Michal Preminger, Director of Business Development
(617) 432-0920
Reference Harvard Case #1603